Overview


According to FutureWise analysis the market for leukemia therapeutics in 2023 is US$ 16.13 billion, and is expected to reach US$ 27.76 billion by 2031 at a CAGR of 7.02%.

The global leukemia therapeutics market growth is steered by factors, for instance, a plethora of available treatment alternatives for treating chronic myeloid leukemia and high prevalence rate of chronic myeloid leukemia are substantially assisting the market growth. For example, in the United States, there were over 20,000 new cases of chronic myeloid leukemia in 2018. Additionally, the segment growth is guided by the ever-increasing ageing population and increasing research funds for cancer treatments and for developing innovative therapies.
Increasing investments for innovative research and development activities in drug development and discovery, growing overall volume of biotechnology companies and is predicted to spur the augmentation of the market. Likewise, the introduction of advanced therapeutics with fewer side effects and more efficiency, pipeline products awaiting approvals and metabolic inhibitors are projected to steer the market growth throughout the forecast timeframe. Rising awareness amongst patients pertaining to recent advancements in technology and advantages, for instance, safety, tolerability and efficacy are the factors projected to boost the market growth. Current research in molecular diagnosis is anticipated to dominate with the accessibility of various leukemia treatments and is projected to expand the global leukemia therapeutics market size.

Due to the soaring insistence for targeted drugs, they are likely to subjugate the global market over the forecast timeframe. The targeted drugs are prominently used due to their higher success rate and efficacy in comparison with chemotherapy and fewer side effects. These factors are the reason for the rise in their sales over the past few years.

The Asia Pacific region is anticipated to rapidly proliferate owing to numerous incomplete needs in the developing markets, for instance, India, Japan and China and growing investments in the expenditure assigned to the research and development by major biotechnology companies. A healthcare infrastructure that is rapidly growing, high penetration rates of the market and increasing levels of awareness are the major factors contributing to the augmentation of the market in the region.

  • Novartis AG
  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Sanofi
  • Pfizer
  • Amgen
  • Gilead Sciences
  • Takeda
  • Celgene

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type of Leukemia

  • Chronic Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukemia

By Treatment Type

  • Targeted Drugs
  • Immunotherapy
  • Chemotherapy

By Molecule Type

  • Small Molecules
  • Biologics

By Mode of Administration

  • Oral Mode
  • Injectable Mode

By Gender

  • Males
  • Females

By Region

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global Leukemia Therapeutics Market By Type Of Leukemia, By Treatment Type, By Molecule Type, By Mode of Administration, By Gender and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Leukemia Therapeutics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Global Leukemia Therapeutics Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.   Global Leukemia Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Leukemia Therapeutics Market, By Type of Leukemia Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Chronic Myeloid Leukemia
        2. Chronic Lymphocytic Leukemia
        3. Acute Lymphocytic Leukemia
        4. Acute Myeloid Leukemia

  • 8.   Global Leukemia Therapeutics Market, By Treatment Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Targeted Drugs
        2. Immunotherapy
        3. Chemotherapy

  • 9.   Global Leukemia Therapeutics Market, By Molecule Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Small Molecules
        2. Biologics

  • 10.   Global Leukemia Therapeutics Market, By Mode of Administration Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Oral Mode
        2. Injectable Mode

  • 11.   Global Leukemia Therapeutics Market, By Gender Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Males
        2. Females

  • 12.   North America Leukemia Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 13.   Latin America Leukemia Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 14.   Europe Leukemia Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe

  • 15.   Asia Pacific Leukemia Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 16.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 17.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 18.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. Novartis AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. AbbVie
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bristol-Myers Squibb
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. F. Hoffmann-La Roche
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Sanofi
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Amgen
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Gilead Sciences
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Takeda
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Celgene
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 19.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients